Related Experiment Video
Updated: Jul 20, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Novel anti-hepatitis B agents: A focus on telbivudine
1St Stephens Centre, Chelsea and Westminster Hospital, London, UK. rachael.jones@chelwest.nhs.uks
Abstract:
Although preventable by vaccination, hepatitis B infection is common, affecting more than 350 million individuals worldwide. Chronic hepatitis B infection is associated with the complications of chronic liver disease including cirrhosis and hepatocellular carcinoma. Current agents designed to target hepatitis B are hindered by the development of resistance, poor tolerability or limited efficacy and a demand for new agents and strategies continues. This review focuses on telbivudine, a novel agent in the fight against hepatitis B.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Antiviral Nucleoside Inhibitors
Hepatitis
Viral Hepatitis I: Introduction
Subviral Agents
Inhibitors Of Virion Release
